Publications by authors named "Lillian K Skidmore"
Mol Cancer Ther
December 2024
Article Synopsis
- Metastatic castration-resistant prostate cancer (mCRPC) is a severe illness that often fails standard treatments, presenting a serious challenge for patient survival.
- ARX517 is a promising new antibody-drug conjugate that targets the prostate-specific membrane antigen (PSMA) with a design that allows for direct delivery of a cytotoxic agent to tumor cells while minimizing premature release.
- Preclinical studies in various prostate cancer models show that ARX517 effectively inhibits tumor growth and has a favorable safety profile, leading to its evaluation in a phase I clinical trial.
